Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out

Pfizer (NYSE: PFE)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it. Even though it looks like cheap stock to own, it continues to fall in value. Over the past 12 months, it's down 18% heading into trading this week. And over a five-year period, it has declined by 30%. There is, however, a compelling case to be made for investing in the business, and that is that Pfizer is continually expanding its pipeline via acquisitions. It's loading up on assets, which give it more potential growth opportunities down the road. For instance, it recently made a move that could help make it a big player in the GLP-1 obesity market.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool